HONG KONG – Foreign investment in Asia’s life science companies is commonplace, but investment groups operating outside the region are often viewed as being less sophisticated or liable to put their money into areas where others fear to tread.
One company seeking to reverse this preconception is Ally Bridge Group (ABG), a pioneer of the “value added cross-border investment...